Inclusion Criteria:

- Acute myeloid leukemia (AML), any subtype including acute promyelocytic leukemia
(APL). Patients with either de novo or secondary AML are eligible.

- No prior AML induction chemotherapy.

- Due to receive standard 3+7 induction chemotherapy using daunorubicin on Days 1-3,
plus cytarabine continuous infusion daily on Days 1-7.

- Age 18 and over.

- Serum bilirubin < or = 1.5 times the upper limit of normal (ULN).

- Serum aspartate aminotransferase and alanine aminotransferase < or = 2.5 times the
ULN.

- Serum creatinine < 200 umol/L

Exclusion Criteria:

- Uncontrolled nausea or vomiting within 48 hours prior to start of induction therapy.
Grade 0-1 nausea is permitted at the start of induction.

- Known hypersensitivity to granisetron or aprepitant.

- Patients currently receiving treatment with strong CYP3A4 inhibitors or substrates
and treatment cannot be either discontinued or switched to a different medication
prior to starting study drug.

- Not able to swallow or absorb oral medications.

- Documented active central nervous system (CNS) leukemia or recent CNS hemorrhage.

- Concomitant use of:

1. Other investigational agents during induction therapy

2. Radiotherapy during, or one month prior to, induction therapy

3. Systemic corticosteroids

4. Other chemotherapy agents on Days 1-8

- Pregnant or breast feeding.